Gulf Pharmaceutical Industries P.S.C. (ADX:JULPHAR)
United Arab Emirates
· Delayed Price · Currency is AED 1.050
-0.030 (-2.78%)
At close: Apr 28, 2026
ADX:JULPHAR Income Statement
Financials in millions AED. Fiscal year is January - December.
Millions AED. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 1,076 | 992.2 | 1,278 | 1,616 | 1,143 | Upgrade
|
| Revenue Growth (YoY) | 8.39% | -22.33% | -20.95% | 41.37% | 99.51% | Upgrade
|
| Cost of Revenue | 639.6 | 585.1 | 852.4 | 1,058 | 759.8 | Upgrade
|
| Gross Profit | 435.9 | 407.1 | 425.1 | 557.9 | 383.4 | Upgrade
|
| Selling, General & Admin | 357.8 | 346.9 | 458.3 | 596.3 | 451.9 | Upgrade
|
| Research & Development | 28.2 | 24.5 | - | - | - | Upgrade
|
| Other Operating Expenses | -4.3 | -10.3 | -8.7 | -9.8 | -110 | Upgrade
|
| Operating Expenses | 381.7 | 361.1 | 449.6 | 586.5 | 341.9 | Upgrade
|
| Operating Income | 54.2 | 46 | -24.5 | -28.6 | 41.5 | Upgrade
|
| Interest Expense | -28.3 | -59.8 | -56.3 | -40.1 | -23.7 | Upgrade
|
| Interest & Investment Income | 7.6 | 2.6 | 6 | 3.6 | 2.4 | Upgrade
|
| Earnings From Equity Investments | - | - | - | - | -31.4 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.1 | 0.7 | - | 0.2 | - | Upgrade
|
| EBT Excluding Unusual Items | 33.6 | -10.5 | -74.8 | -64.9 | -11.2 | Upgrade
|
| Gain (Loss) on Sale of Investments | 4.4 | 3.3 | 3.5 | 2 | -5.5 | Upgrade
|
| Asset Writedown | -0.9 | -1.5 | - | - | - | Upgrade
|
| Other Unusual Items | 10.3 | 2.1 | 1.5 | 29.5 | 59.3 | Upgrade
|
| Pretax Income | 47.4 | -6.6 | -69.8 | -33.4 | 42.6 | Upgrade
|
| Income Tax Expense | 3.5 | 2.7 | 6.1 | 2.8 | 1.1 | Upgrade
|
| Earnings From Continuing Operations | 43.9 | -9.3 | -75.9 | -36.2 | 41.5 | Upgrade
|
| Earnings From Discontinued Operations | 129.4 | 54.2 | -22.6 | 4.5 | 17.9 | Upgrade
|
| Net Income to Company | 173.3 | 44.9 | -98.5 | -31.7 | 59.4 | Upgrade
|
| Minority Interest in Earnings | -1.1 | -0.3 | -0.6 | 2.3 | 5 | Upgrade
|
| Net Income | 172.2 | 44.6 | -99.1 | -29.4 | 64.4 | Upgrade
|
| Net Income to Common | 172.2 | 44.6 | -99.1 | -29.4 | 64.4 | Upgrade
|
| Net Income Growth | 286.10% | - | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 1,155 | 1,155 | 1,155 | 1,155 | 1,155 | Upgrade
|
| Shares Outstanding (Diluted) | 1,155 | 1,155 | 1,155 | 1,155 | 1,155 | Upgrade
|
| Shares Change (YoY) | - | - | - | - | 9.21% | Upgrade
|
| EPS (Basic) | 0.15 | 0.04 | -0.09 | -0.03 | 0.06 | Upgrade
|
| EPS (Diluted) | 0.15 | 0.04 | -0.09 | -0.03 | 0.06 | Upgrade
|
| EPS Growth | 286.11% | - | - | - | - | Upgrade
|
| Free Cash Flow | 85.2 | 146.3 | 71.5 | -44.4 | 1.8 | Upgrade
|
| Free Cash Flow Per Share | 0.07 | 0.13 | 0.06 | -0.04 | 0.00 | Upgrade
|
| Gross Margin | 40.53% | 41.03% | 33.28% | 34.52% | 33.54% | Upgrade
|
| Operating Margin | 5.04% | 4.64% | -1.92% | -1.77% | 3.63% | Upgrade
|
| Profit Margin | 16.01% | 4.50% | -7.76% | -1.82% | 5.63% | Upgrade
|
| Free Cash Flow Margin | 7.92% | 14.74% | 5.60% | -2.75% | 0.16% | Upgrade
|
| EBITDA | 98.2 | 138.2 | 74.9 | 66.5 | 128.5 | Upgrade
|
| EBITDA Margin | 9.13% | 13.93% | 5.86% | 4.12% | 11.24% | Upgrade
|
| D&A For EBITDA | 44 | 92.2 | 99.4 | 95.1 | 87 | Upgrade
|
| EBIT | 54.2 | 46 | -24.5 | -28.6 | 41.5 | Upgrade
|
| EBIT Margin | 5.04% | 4.64% | -1.92% | -1.77% | 3.63% | Upgrade
|
| Effective Tax Rate | 7.38% | - | - | - | 2.58% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.